Avelumab and Merkel Cell Carcinoma: Long-Term Outcomes and Prognosis After Exposure

From General Health Principles to Targeted Immunotherapy

The legacy of general health and science information has long emphasized broad preventive measures and population-level wellness, often focusing on lifestyle factors and environmental influences. Within this framework, public health messaging has historically addressed cancer risk through generalized guidance on sun exposure, vaccination, and immune system maintenance. This foundation provides a critical backdrop for understanding how specific therapeutic interventions intersect with disease outcomes. Transitioning from this broad context, attention now turns to the targeted use of immunotherapeutic agents in oncology. The introduction of checkpoint inhibitors has reshaped treatment paradigms for several malignancies, including those with viral associations. In particular, the programmed death-ligand 1 inhibitor Avelumab has been evaluated for its role in Merkel cell carcinoma, a rare but aggressive skin cancer often linked to polyomavirus infection. Clinical observations regarding long-term outcomes following Avelumab exposure raise important considerations about prognosis and disease management.

Avelumab: Mechanism and Approval in Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is the first therapeutic agent specifically approved for this indication and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Efficacy and Challenges in Long-Term Management

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who become refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, five patients with metastatic MCC who were refractory to avelumab were subsequently treated with combined ipilimumab and nivolumab. Three out of five patients responded to this combination therapy according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on the use of ipilimumab plus nivolumab in avelumab-refractory MCC, further supporting this approach as a potential salvage therapy (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study confirmed that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab currently approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Adverse Effects and Prognostic Considerations

Regarding adverse effects, checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab. The hypercalcaemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case highlights the potential for avelumab to trigger immune-mediated complications, which require careful monitoring and management. The adequacy of warnings regarding avelumab and MCC is supported by the drug's approval status and the availability of clinical trial data demonstrating its efficacy and safety profile. However, the risk of progression in approximately half of treated patients underscores the need for ongoing surveillance and alternative treatment strategies. Prognosis-related considerations for affected patients include the potential for durable responses in those who respond to avelumab, but also the poor prognosis associated with refractory disease. The timeline between avelumab exposure and documented harm varies; immune-related adverse events can occur during treatment, while progression may be observed after initial response or as primary resistance. For patients who progress, the timeline to subsequent therapy and response is critical, as evidenced by the use of ipilimumab plus nivolumab in avelumab-refractory cases.

Summary and Future Directions

In summary, avelumab represents a significant therapeutic advance for metastatic MCC, with a well-characterized efficacy profile and manageable immune-related adverse events. However, the high rate of progression and the need for effective salvage therapies remain important clinical challenges. Ongoing research into combination regimens and alternative checkpoint inhibitors continues to shape the management of this aggressive malignancy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Avelumab and how does it work in Merkel cell carcinoma?

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) and works by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells.

What are the long-term outcomes for patients with Merkel cell carcinoma treated with Avelumab?

Long-term outcomes vary: approximately one-third of patients achieve objective responses, and response rates to PD-1/PD-L1 inhibition can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, about 50% of patients progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For those who respond, durable responses are possible, but refractory disease carries a poor prognosis.

What are the common adverse effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may include conditions like hypercalcaemia from sarcoidosis reactivation, which can be managed with corticosteroids. Monitoring for irAEs is essential during treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.